Assessment of the efficacy of rosuvastatin in patient groups with a dissimilar risk profile in an observational study (HEROS) - HEROS
Study identifier:25V07
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Assessment of the efficacy of rosuvastatin in patient groups with a dissimilar risk profile in an observational study (HEROS)
Medical condition
Hypercholesterolemia
Phase
-
Healthy volunteers
No
Study drug
Rosuvastatin
Sex
All
Actual Enrollment
-
Study type
Observational
Age
18 Years - 75 Years
Date
Study Start Date: 01 May 2003
Primary Completion Date: -
Study Completion Date: 01 Apr 2005
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca | Drug: Rosuvastatin Oral Other Name: Crestor |
Contacts
Investigators
Principal Investigator
Ingrid van Geel
CV
